Toxic antibody is the latest weapon that has great potential for treating various forms of cancer.
Under the name of the "Trojan horse" approach to chemotherapy, the new drug proved to be worthy of advancing through the chain of clinical trials to test more patients. This is not a legendary treatment, but such an approach can be as close as we get.
Researchers from the Cancer Research Institute in London and The Royal Marsden NHS Foundation Trust have reviewed a new clinical trial in which 147 patients took part to evaluate its potential benefits and side effects risks.
Just a TV for short, the drug consists of a monoclonal antibody, and a cytotoxic component that can lethally damage the cells.
Antibody, if you want, is a gift of a fascinating horse at the enemy's door ̵
Although all types of healthy cells have this factor, a wide range of tumors exploits it as a method get out of control, making it an attractive target for cytotoxic searches and destroy chemical weapons.
In this case, the component whose task is this bloody work, is monomethyl aurastatin E, a molecule that interferes with the reproduction of cells.
The mechanism of action is completely new – it acts as a Trojan horse to penetrate cancer cells and kill them from within, "says Oncologist Johan de Bono of the Cancer Research Institute
"Our early study shows that it has the potential to treat a large number of different types of cancer, and especially some of those with very low survival rates."
They included cervical, bladder, ovarian, endometrial, esophagus and lung cancer
The most striking was the reaction of those with bladder cancer, 27 percent of the volunteers surveyed observed stabilization of the disease. At the other end, there was an endometrial cancer, with a more modest 7% of the subjects improving.
"It's fun to see the potential that a television set displays in a number of hard-to-treat cancer cases," says Head of the Cancer Research Institute.
"I look forward to seeing his progress in the clinic and I hope he can benefit patients who are currently not exhausted by treatment options." Phase I of the clinical trials began in 2013 with the safety testing of television only for 27 patients. One and a half years later, there were serious health problems, including signs of severe type 2 diabetes, mucosal inflammation and fever.
Lower doses were reduced, although treatment was still far from problems, with nasal bleeding, nausea and fatigue among common complaints.
However, when it comes to life or death, non-fatal ailments such as these may seem trivial in comparison. Phase I testing allowed Phase II, where the TV could make a big difference for many cancer patients. tests, all of which had cancer at a late stage, which was heavily pretreated with other drugs and did not exhaust other options, says de Bono. intestines and pancreas, during testing as a second-line drug for cervical cancer that has not died after initial treatment.
It is important to note that this is not a panacea, or the end of cancer, as we know it. . But when so many promising treatments do not have time to go beyond the starting line, the promise is that the promise can affect a wide range of types of cancers.
If everything goes well, we can expect a third stage of testing. For several years, where the efficacy and safety of the drug are compared with similar treatments
It takes time and money, so we can not expect that television will become available for some time (if at all). But the success of the age-old military strategy used in the antitumor drug is well-suited for the treatment of this type.
"We desperately need innovative treatments like those that can attack cancer in new ways and remain effective even against tumors that become resistant to standard therapy," says Workman.
This study was published in ] Oncology Lancet .